Article Versions Notes

Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, et al. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers. 2022; 14(17):4079. https://doi.org/10.3390/cancers14174079

Hilton, John, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, William Edenfield, Geoffrey I. Shapiro, Michael L. Cheng, Jacqueline Vuky, Bradley Corr, and et al. 2022. "BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial" Cancers 14, no. 17: 4079. https://doi.org/10.3390/cancers14174079

Hilton, J., Cristea, M., Postel-Vinay, S., Baldini, C., Voskoboynik, M., Edenfield, W., Shapiro, G. I., Cheng, M. L., Vuky, J., Corr, B., Das, S., Apfel, A., Xu, K., Kozicki, M., Ünsal-Kaçmaz, K., Hammell, A., Wang, G., Ravindran, P., Kollia, G., ... Diamond, J. R. (2022). BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers, 14(17), 4079. https://doi.org/10.3390/cancers14174079